Discontinued — last reported Q4 '21
MetLife Short-Term Borrowings increased by 13.8% to $404.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 6.0%, from $381.00M to $404.00M. Over 5 years (FY 2020 to FY 2025), Short-Term Borrowings shows relatively stable performance with a -2.0% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
High levels may indicate a reliance on short-term credit markets for operational cash flow, which can increase liquidity risk.
Short-term borrowings consist of debt obligations that are due within one year, excluding the current portion of long-te...
Varies by industry; pharmaceutical firms often maintain access to short-term credit for operational flexibility.
short_term_borrowings| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $393.00M | $346.00M | $341.00M | $323.00M | $196.00M | $183.00M | $175.00M | $168.00M | $200.00M | $161.00M | $119.00M | $127.00M | $390.00M | $404.00M | $465.00M | $381.00M | $379.00M | $378.00M | $355.00M | $404.00M |
| QoQ Change | — | -12.0% | -1.4% | -5.3% | -39.3% | -6.6% | -4.4% | -4.0% | +19.0% | -19.5% | -26.1% | +6.7% | +207.1% | +3.6% | +15.1% | -18.1% | -0.5% | -0.3% | -6.1% | +13.8% |
| YoY Change | — | — | — | — | -50.1% | -47.1% | -48.7% | -48.0% | +2.0% | -12.0% | -32.0% | -24.4% | +95.0% | +150.9% | +290.8% | +200.0% | -2.8% | -6.4% | -23.7% | +6.0% |